228 related articles for article (PubMed ID: 8091766)
61. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent.
Collins MT; Skarulis MC; Bilezikian JP; Silverberg SJ; Spiegel AM; Marx SJ
J Clin Endocrinol Metab; 1998 Apr; 83(4):1083-8. PubMed ID: 9543122
[TBL] [Abstract][Full Text] [Related]
62. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
[TBL] [Abstract][Full Text] [Related]
63. [Primary hyperparathyroidism. An alternative to the surgery].
Díaz Guardiola P; Vega Piñero B; Alameda Hernando C; Pavón de Paz I; Iglesias Bolaños P; Guijarro de Armas G
Endocrinol Nutr; 2009 Mar; 56(3):132-5. PubMed ID: 19627726
[TBL] [Abstract][Full Text] [Related]
64. [Therapy of hypercalcemia with ibandronate in case of acute renal failure].
Bergner R; Henrich DM; Hoffmann M; Bruckner D; Uppenkamp M
Internist (Berl); 2006 Mar; 47(3):293-6. PubMed ID: 16470360
[TBL] [Abstract][Full Text] [Related]
65. Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism.
Evans RA
Aust N Z J Med; 1987 Feb; 17(1):58-9. PubMed ID: 3476049
[TBL] [Abstract][Full Text] [Related]
66. Effect of pamidronate in a rat hypercalcemia model induced by cholecalciferol.
Okada M; Noguchi S; Hasegawa Y; Inukai T
Arzneimittelforschung; 1992 Apr; 42(4):543-6. PubMed ID: 1322674
[TBL] [Abstract][Full Text] [Related]
67. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.
Serra AL; Schwarz AA; Wick FH; Marti HP; Wüthrich RP
Nephrol Dial Transplant; 2005 Jul; 20(7):1315-9. PubMed ID: 15941845
[TBL] [Abstract][Full Text] [Related]
68. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.
Gallacher SJ; Fraser WD; Logue FC; Dryburgh FJ; Cowan RA; Boyle IT; Ralston SH
Calcif Tissue Int; 1992 Dec; 51(6):419-23. PubMed ID: 1333351
[TBL] [Abstract][Full Text] [Related]
69. Studies in patients with hyperparathyroidism using a new two-site immunochemiluminometric assay for circulating intact (1-84) parathyroid hormone.
Curley IR; Wheeler MH; Aston JP; Brown RC; Weeks I; Woodhead JS
Surgery; 1987 Dec; 102(6):926-31. PubMed ID: 3686355
[TBL] [Abstract][Full Text] [Related]
70. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population.
Lee JK; Chuang MJ; Lu CC; Hao LJ; Yang CY; Han TM; Lam HC
J Endocrinol Invest; 1997; 20(7):404-9. PubMed ID: 9309539
[TBL] [Abstract][Full Text] [Related]
71. Humoral hypercalcemia of pregnancy treated with bisphosphonates.
Koren R; Neeman O; Koren S; Benbassat CA
Arch Endocrinol Metab; 2018 Feb; 62(1):125-128. PubMed ID: 29694631
[TBL] [Abstract][Full Text] [Related]
72. The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.
Lee DC; Lee GY
J Toxicol Clin Toxicol; 1998; 36(7):719-21. PubMed ID: 9865241
[TBL] [Abstract][Full Text] [Related]
73. Fasting serum gastrin in primary hyperparathyroidism and in chronic hypercalcemia.
Vantini I; Cominacini L; Ederle A; Galvanini G; Piubello W; Adami S; Cavallini G; Lo Cascio V
Acta Hepatogastroenterol (Stuttg); 1979 Dec; 26(6):472-7. PubMed ID: 549429
[TBL] [Abstract][Full Text] [Related]
74. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
Mannix KA; Carmichael J; Harris AL; Cantwell BM
Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
[TBL] [Abstract][Full Text] [Related]
75. Phosphate depletion in the rat: effect of bisphosphonates and the calcemic response to PTH.
Jara A; Lee E; Stauber D; Moatamed F; Felsenfeld AJ; Kleeman CR
Kidney Int; 1999 Apr; 55(4):1434-43. PubMed ID: 10201008
[TBL] [Abstract][Full Text] [Related]
76. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism.
Christensen SE; Nissen PH; Vestergaard P; Heickendorff L; Rejnmark L; Brixen K; Mosekilde L
Eur J Endocrinol; 2008 Dec; 159(6):719-27. PubMed ID: 18787045
[TBL] [Abstract][Full Text] [Related]
77. Severe Hypercalcemia in a Child With Acute Lymphoblastic Leukemia Relapse: Successful Management With Combination of Calcitonin and Bisphosphonate.
Tagiyev A; Demirbilek H; Tavil B; Buyukyilmaz G; Gumruk F; Cetin M
J Pediatr Hematol Oncol; 2016 Apr; 38(3):232-4. PubMed ID: 26907650
[TBL] [Abstract][Full Text] [Related]
78. Intravenous pamidronic acid in hypercalcemia due to parathyroid carcinoma.
Vega EM; Mautalen CA
Medicina (B Aires); 1991; 51(2):106-10. PubMed ID: 1820495
[TBL] [Abstract][Full Text] [Related]
79. Pamidronate treatment for hypercalcemia in an infant receiving parenteral nutrition.
Bryowsky JJ; Bugnitz MC; Hak EB
Pharmacotherapy; 2004 Jul; 24(7):939-44. PubMed ID: 15303458
[TBL] [Abstract][Full Text] [Related]
80. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
Pecherstorfer M; Herrmann Z; Body JJ; Manegold C; Degardin M; Clemens MR; Thürlimann B; Tubiana-Hulin M; Steinhauer EU; van Eijkeren M; Huss HJ; Thiébaud D
J Clin Oncol; 1996 Jan; 14(1):268-76. PubMed ID: 8558208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
